Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: An initial experience

Journal of Computer Assisted Tomography

Volumn 32, Issue 6, 2008, Pages 987-994

  Hsieh, Tsyh Jyi ^a   Li, Chun Wei ^a   Chuang, Hung Yi ^a,b   Liu, Gin Chung ^a,b   Wang, Chien Kuo ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NONE   (Taiwan)

Author keywords

Chemotherapy; Magnetic resonance imaging; Magnetic resonance spectroscopy; Musculoskeletal tumors

Indexed keywords

BONE; CHEMOTHERAPY; DIAGNOSIS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE SPECTROSCOPY; MAGNETISM; NUCLEAR MAGNETIC RESONANCE; SCANNING; SPECTRUM ANALYSIS; TUMORS;

BONE TISSUE; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; FOLLOW UP; IN-VIVO; MUSCULOSKELETAL TUMORS; PROTON MAGNETIC RESONANCE SPECTROSCOPIES; SOFT TISSUE TUMOR; SURFACE COILS; VOLUME RATIO; WATER RATIO;

MAGNETIC RESONANCE IMAGING;

ANTINEOPLASTIC AGENT; CHOLINE; GADOLINIUM PENTETATE; WATER; DIAGNOSTIC AGENT; PROTON; TUMOR MARKER;

ADULT; ALVEOLAR SOFT PART SARCOMA; ARTICLE; BONE CANCER; CANCER CHEMOTHERAPY; CASE REPORT; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; KRUSKAL WALLIS TEST; LONGITUDINAL STUDY; LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; PATIENT MONITORING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SOFT TISSUE CANCER; EVALUATION; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PILOT STUDY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PILOT PROJECTS; PROTONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 62149111108     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e31815b9ce9     Document Type: Article

References (37)

1. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
2. Husband JE. Monitoring tumour response. Eur Radiol. 1996;6:775-785.
3. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6:931-933.
4. Berquist TH, Ehman RL, King BF, et al. Value of MR imaging in differentiating benign from malignant soft-tissue masses: study of 95 lesions. Am J Roentgenol. 1990;155:1251-1255.
5. Holscher HC, Bloem JL, Nooy MA, et al. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. Am J Roentgenol. 1990;154:763-769.
6. Totty WG, Murphy WA, Lee JK. Soft-tissue tumors: MR imaging. Radiology. 1986;160:135-141.
7. Crim JR, Seeger LL, Yao L, et al. Diagnosis of soft-tissue masses with MR imaging: can benign masses be differentiated from malignant ones? Radiology. 1992;185:581-586.
8. Sundaram M, McGuire MH, Schajowicz F. Soft-tissue masses: histologic basis for decreased signal (short T2) on T2-weighted MR images. Am J Roentgenol. 1987;148:1247-1250.
9. Verstraete KL, De Deene Y, Roels H, et al. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging-parametric "first-pass" images depict tissue vascularization and perfusion. Radiology. 1994;192:835-843.
10. Erlemann R, Reiser MF, Peters PE, et al. Musculoskeletal neoplasms: static and dynamic Gd-DTPA-enhanced MR imaging. Radiology. 1989; 171:767-773.
11. Verstraete KL, Dierick A, De Deene Y, et al. First-pass images of musculoskeletal lesions: a new and useful diagnostic application of dynamic contrast-enhanced MRI. Magn Reson Imaging. 1994; 12:687-702.
12. Van Rijswijk CS, Geirnaerdt MJ, Hogendoorn PC, et al. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology. 2004;233:493-502.
13. Fletcher BD, Reddick WE, Taylor JS. Dynamic MR imaging of musculoskeletal neoplasms. Radiology. 1996;200:869-872.
14. Fletcher BD, Hanna SL. Musculoskeletal neoplasms: dynamic Gd-DTPA-enhanced MR imaging. Radiology. 1990;177:287-288.
15. Brandao LA, Domingus RC. MR Spectroscopy of the Brain. Philadelphia, PA: Lippincott Williams and Wilkins; 2004.
16. 1H MR spectroscopy: initial results. Radiology. 2004;232:599-605.
17. Millis K, Weybright P, Campbell N, et al. Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magn Reson Med. 1999;41:257-267.
18. Mukherji SK, Schiro S, Castillo M, et al. Proton MR spectroscopy of squamous cell carcinoma of the extracranial head and neck: in vitro and in vivo studies. Am J Neuroradiol. 1997;18:1057-1072.
19. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992;5:303-324.
20. Oya N, Aoki J, Shinozaki T, et al. Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor. Radiat Med. 2000;18:193-198.
21. Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging. 1999;10:159-164.
22. Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy - initial results. Radiology. 2001;220:40-46.
23. Gribbestad IS, Singstad TE, Nilsen G, et al. In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging. 1998;8:1191-1197.
24. 3) spatial resolution. Radiology. 1996;198: 795-805.
25. Allen JR, Prost RW, Griffith OW, et al. In vivo proton (H1) magnetic resonance spectroscopy for cervical carcinoma. Am J Clin Oncol. 2001;24:522-529.
26. Mukherji SK, Gerstle RJ. In vitro 1H MR spectroscopy of squamous cell carcinoma of the extracranial head and neck. qNeuroimaging Clin N Am. 1998;8:835-847.
27. Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer. 2001;84:1016-1022.
28. 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br J Radiol. 2002;75:959-966.
29. 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed. 1991;4: 47-52.
30. Ruiz-Cabello J, Cohen JS. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 1992;5:226-233.
31. Tong Z, Yamaki T, Harada K, et al. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. Magn Reson Imaging. 2004; 22:735-742.
32. 1H -MRS using water as an internal standard. Magn Reson Imaging. 1993;11:107-118.
33. 1H NMR spectroscopy in vivo, ex vivo, and in vitro. J Biol Chem. 2003;278: 45915-45923.
34. Boesch C, Kreis R. Dipolar coupling and ordering effects observed in magnetic resonance spectra of skeletal muscle. NMR Biomed. 2001;14:140-148.
35. Casciani E, Polettini E, Bertini L, et al. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiol Med (Torino). 2004;108:530-541.
36. 1H -magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. Eur Radiol. 2005;15:645-652.
37. Vigneron D, Bollen A, McDermott M, et al. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn Reson Imaging. 2001;19:89-101.